Увійти

Готові списки джерел за темами / Minimal Residual Disease Detection / Книги

Книги з теми "Minimal Residual Disease Detection"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Minimal Residual Disease Detection.

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-37 книг для дослідження на тему "Minimal Residual Disease Detection".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте книги для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Druley, Todd E., ed. Minimal Residual Disease Testing. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-94827-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Reinhold, Uwe, and Wolfgang Tilgen, eds. Minimal Residual Disease in Melanoma. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Hagenbeek, Anton, and Bob Löwenberg, eds. Minimal Residual Disease in Acute Leukemia 1986. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Aguirre-Ghiso, Julio A., ed. Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-97746-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Ignatiadis, Michail, Christos Sotiriou, and Klaus Pantel, eds. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28160-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2010.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Tilgen, W., and U. Reinhold. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Tilgen, W., and U. Reinhold. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance. Springer London, Limited, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

(Editor), U. Reinhold, and W. Tilgen (Editor), eds. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance (Recent Results in Cancer Research). Springer, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Minimal Residual Disease in Leukaemia. Elsevier, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

L, Foroni, and Hoffbrand A. V, eds. Minimal residual disease investigation in haematological malignancies. London: Baillière Tindall, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

A, Hagenbeek, and Löwenberg B. 1946-, eds. Minimal residual disease in acute leukemia, 1986. Dordrecht: Nijhoff, 1986.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia 1986. Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Hagenbeek, A. Minimal Residual Disease in Acute Leukemia 1986. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

(Editor), Pia Raanani, and Andreas Hochhaus (Editor), eds. Minimal Residual Disease In Hematologic Malignancies (Acta Haematologica 2004). Not Avail, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Aguirre-Ghiso, Julio A. Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Springer, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Druley, Todd E. Minimal Residual Disease Testing: Current Innovations and Future Directions. Springer, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Minimal Residual Disease And Circulating Tumor Cells In Breast Cancer. Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

(Editor), A. Hagenbeek, and B. Löwenberg (Editor), eds. Minimal Residual Disease in Acute Leukemia 1986 (Developments in Oncology). Springer, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer Berlin / Heidelberg, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Bonadonna, Gianni, and Georges Mathé. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Brand: Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Bonadonna, Gianni, G. Mathe, and S. E. Salmon. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Clifford, Michael. Children with Congenital Heart Disease for Non-cardiac Surgery. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199764495.003.0030.

Повний текст джерела

Анотація:

It is estimated that up to 1 million children in the United States have congenital heart disease (CHD). These children range from those who are essentially normal functionally with anatomically repaired hearts, and hence minimal impact for anesthesia, to those that have had complex and numerous surgical procedures with significant residual abnormalities in circulation and cardiac function, and a range of comorbidities. These latter children have many issues that will affect anesthesia for non-cardiac surgery. When presented with a child with CHD for non-cardiac surgery, the general pediatric anesthesiologist should be able to perform a tailored cardiac preoperative evaluation and plan an appropriate anesthetic with suitable anesthetic techniques, agents, and monitoring. Not every child with CHD has a single ventricle with all its complexity (see Chapter 31), but every child with CHD will offer challenges for the pediatric anesthesiologist.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Повний текст джерела

Анотація:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Bebell, Lisa M. Ebola and Other Filoviruses. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0002.

Повний текст джерела

Анотація:

Congenital and pediatric Ebola virus disease (EVD) and Marburg virus disease (MVD) are severe, even lethal infections. Historically, children have been underrepresented in filovirus disease outbreaks, and evidence-based treatment strategies are lacking. Existing data suggest that case fatalities are highest among children under four years of age, which is partially explained by higher virus concentrations in young children. Prevention and aggressive resuscitation, nutrition, and supportive care are the mainstays of management until filovirus-specific therapies can be developed. Differences in pediatric immune and inflammatory responses may necessitate unique approaches to pediatric vaccination and treatment. There are minimal safety or immunogenicity data in children, a crucial knowledge gap that must be addressed in future trials. Studying pediatric survivors of the 2014–2016 West Africa EVD outbreak will provide much-needed data on long-term outcomes and residual effects of filovirus disease while we await effective filovirus-specific vaccines and therapies.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Martin-Loeches, Ignacio, and Antonio Artigas. Respiratory support with positive end-expiratory pressure. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0094.

Повний текст джерела

Анотація:

Positive-end-expiratory pressure (PEEP) is the pressure present in the airway (alveolar pressure) above atmospheric pressure that exists at the end of expiration. The term PEEP is defined in two particular settings. Extrinsic PEEP (applied by ventilator) and intrinsic PEEP (PEEP caused by non-complete exhalation causing progressive air trapping). Applied (extrinsic) PEEP—is usually one of the first ventilator settings chosen when mechanical ventilation (MV) is initiated. Applying PEEP increases alveolar pressure and volume. The increased lung volume increases the surface area by reopening and stabilizing collapsed or unstable alveoli. PEEP therapy can be effective when used in patients with a diffuse lung disease with a decrease in functional residual capacity. Lung protection ventilation is an established strategy of management to reduce and avoid ventilator-induced lung injury and mortality. Levels of PEEP have been traditionally used from 5 to 12 cmH2O; however, higher levels of PEEP have also been proposed and updated in order to keep alveoli open, without the cyclical opening and closing of lung units (atelectrauma). The ideal level of PEEP is that which prevents derecruitment of the majority of alveoli, while causing minimal overdistension; however, it should be individualized and higher PEEP might be used in the more severe end of the spectrum of patients with improved survival. A survival benefit for higher levels of PEEP has not been yet reported for any patient under MV, but a higher PaO2/FiO2 ratio seems to be better in the higher PEEP group.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Lee, Amie Y., and Bonnie N. Joe. Post-Lumpectomy/Post-Radiation Breast. Edited by Christoph I. Lee, Constance D. Lehman, and Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0062.

Повний текст джерела

Анотація:

Mammography is currently the primary imaging modality for post-operative evaluation and surveillance of the conservatively treated breast. Tumor recurrence has been shown to occur at a rate of approximately 1–2% per year, and the goal of imaging surveillance is to detect recurrent and new cancers at the earliest stages while avoiding unnecessary biopsies for characteristically benign findings. The radiologist should be familiar with the expected mammographic appearance and evolution of benign post-lumpectomy/post-radiation change, while also recognizing findings suspicious for residual and recurrent disease. This chapter, appearing in the section on intervention and surgical changes, reviews the key imaging and clinical features, imaging protocols and pitfalls, and clinical recommendations for the post-lumpectomy and post-radiation breast. Topics discussed include the evolution of benign post-surgical/post-radiation findings and the detection of suspicious lesions. The primary emphasis will be on mammographic surveillance. The role of ultrasound and MRI will also be discussed.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!